Liang et al., 2024 - Google Patents
pH/glutathione dual-responsive copper sulfide-coated organic mesoporous silica for synergistic chemo-photothermal therapyLiang et al., 2024
- Document ID
- 8236175510174168421
- Author
- Liang J
- Ling J
- Zhang X
- Ouyang X
- Omer A
- Yang G
- Publication year
- Publication venue
- Journal of Colloid and Interface Science
External Links
Snippet
Nanodrug delivery systems (NDSs), such as mesoporous silica, have been widely studied because of their high specific surface area, high loading rate, and easy modification; however, they are not easily metabolized and excreted by the human body and may be …
- OMZSGWSJDCOLKM-UHFFFAOYSA-N copper(II) sulfide data:image/svg+xml;base64,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 data:image/svg+xml;base64,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 [S-2].[Cu+2] 0 title abstract description 168
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
- A61K47/48861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
- A61K47/48876—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being a solid micro- or nanoparticle having no hollow or gas-filled core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
- A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Niu et al. | Hollow mesoporous silica nanoparticles gated by chitosan-copper sulfide composites as theranostic agents for the treatment of breast cancer | |
Bagheri et al. | Silica based hybrid materials for drug delivery and bioimaging | |
Hu et al. | Ultrasmall Cu2-xS nanodots as photothermal-enhanced Fenton nanocatalysts for synergistic tumor therapy at NIR-II biowindow | |
Yang et al. | Multifunctional and stimuli‐responsive magnetic nanoparticle‐based delivery systems for biomedical applications | |
Zhang et al. | Functionalized MoS2-nanosheets for targeted drug delivery and chemo-photothermal therapy | |
Moreira et al. | Stimuli-responsive mesoporous silica nanoparticles for cancer therapy: A review | |
Kumar et al. | Mesoporous silica nanoparticles as cutting-edge theranostics: Advancement from merely a carrier to tailor-made smart delivery platform | |
Li et al. | Biodegradable theranostic nanoplatforms of albumin-biomineralized nanocomposites modified hollow mesoporous organosilica for photoacoustic imaging guided tumor synergistic therapy | |
M Rosenholm et al. | Multifunctional mesoporous silica nanoparticles for combined therapeutic, diagnostic and targeted action in cancer treatment | |
Zhao et al. | Outside-in synthesis of mesoporous silica/molybdenum disulfide nanoparticles for antitumor application | |
Yang et al. | Two-dimensional magnetic WS2@ Fe3O4 nanocomposite with mesoporous silica coating for drug delivery and imaging-guided therapy of cancer | |
Zhu et al. | Photosensitizer (PS)/polyhedral oligomeric silsesquioxane (POSS)-crosslinked nanohybrids for enhanced imaging-guided photodynamic cancer therapy | |
Liang et al. | pH/glutathione dual-responsive copper sulfide-coated organic mesoporous silica for synergistic chemo-photothermal therapy | |
Al-Rawi et al. | Magnetism in drug delivery: The marvels of iron oxides and substituted ferrites nanoparticles | |
Mu et al. | Unsaturated nitrogen-rich polymer poly (l-histidine) gated reversibly switchable mesoporous silica nanoparticles using “graft to” strategy for drug controlled release | |
Zhao et al. | Transferrin modified ruthenium nanoparticles with good biocompatibility for photothermal tumor therapy | |
Zhu et al. | Hyaluronic acid-encapsulated platinum nanoparticles for targeted photothermal therapy of breast cancer | |
Chen et al. | Recent developments of mesoporous silica nanoparticles in biomedicine | |
Gao et al. | AuNRs@ MIL-101-based stimuli-responsive nanoplatform with supramolecular gates for image-guided chemo-photothermal therapy | |
Lee et al. | Mannosylated poly (acrylic acid)-coated mesoporous silica nanoparticles for anticancer therapy | |
Luo et al. | Recent Progress in Macromolecule‐Anchored Hybrid Gold Nanomaterials for Biomedical Applications | |
Ashrafizadeh et al. | Photoactive polymers-decorated Cu-Al layered double hydroxide hexagonal architectures: A potential non-viral vector for photothermal therapy and co-delivery of DOX/pCRISPR | |
Zhu et al. | Redox and pH dual sensitive carboxymethyl chitosan functionalized polydopamine nanoparticles loaded with doxorubicin for tumor chemo-photothermal therapy | |
Amiryaghoubi et al. | Smart chitosan–folate hybrid magnetic nanoparticles for targeted delivery of doxorubicin to osteosarcoma cells | |
Lee et al. | Facile fabrication of highly photothermal-effective albumin-assisted gold nanoclusters for treating breast cancer |